03:01 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

A pathway to Biopharma 3.0

As market and social forces continue to tighten around the biopharmaceutical industry, drug companies need to start evolving toward a new business model that both capitalizes on the potential of new technologies and accommodates society’s...
16:14 , Apr 27, 2018 |  BC Week In Review  |  Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
19:52 , Apr 20, 2018 |  BC Extra  |  Company News

UCB buys rights to seizure candidate

UCB S.A. (Euronext:UCB) acquired rights to intranasal midazolam (USL261) from the Proximagen LLC subsidiary of Acova Inc. (Plymouth, Minn.). Proximagen will receive $150 million up front and is eligible for $220 million in milestones. The...
00:38 , Jan 6, 2018 |  BioCentury  |  Finance

Burgeoning bellwethers

  The miserable performance of large cap biotechs last quarter is likely to be a boon for small- and mid-cap players this year, in more ways than one. Buysiders spent most of 2017 focusing to...
20:22 , Nov 3, 2017 |  BioCentury  |  Regulation

Frame work

A little over four years into its implementation, FDA’s structured benefit-risk framework appears to be meeting its objectives of creating transparency into its approval decisions. The agency began to incorporate the framework templates into its...
00:40 , Feb 3, 2017 |  BC Week In Review  |  Clinical News

Briviact regulatory update

FDA accepted for review an sNDA from UCB for Briviact brivaracetam as monotherapy to treat partial-onset seizures in epileptics ages ≥16. Last year, the agency approved the high affinity synaptic vesicle protein (SV2A) ligand as...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
07:00 , Jun 6, 2016 |  BC Week In Review  |  Company News

UCB sales and marketing update

UCB launched Briviact brivaracetam in the U.S. to treat partial-onset seizures in epileptics ages 16 and older. The high affinity synaptic vesicle protein (SV2A) ligand is available in three formulations: tablet; oral solution; and injection....
07:00 , Apr 4, 2016 |  BioCentury  |  Finance

1Q approvals

1Q approvals...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Company News

UCB sales and marketing update

UCB launched Briviact brivaracetam in the U.K. as an adjunct therapy to treat partial-onset seizures in epileptics ages 16 and older. The company said the high affinity synaptic vesicle protein (SV2A) ligand costs L4.63 ($6.42)...